Drug Profile
Teropavimab - Frontier Biotechnologies/Gilead Sciences
Alternative Names: 3BNC 117; 3BNC 117LS; 3BNC117-LS-J; GS-5423Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Rockefeller University
- Developer irsiCaixa Foundation; Rockefeller University; University of Cologne
- Class Antiretrovirals; Monoclonal antibodies
- Mechanism of Action HIV envelope protein gp120 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 01 Apr 2024 National Institute of Allergy and Infectious Diseases in collaboration with Gilead Sciences initiates a phase I/II trial in HIV 1 infections (Combination therapy, Treatment-experienced) in USA (NCT06071767)
- 05 Mar 2024 Efficacy and adverse event data from phase Ib trial in HIV-1-infections released by Gilead Sciences
- 08 Jan 2024 National Institute of Allergy and Infectious Diseases in collaboration with AIDS Clinical Trials Group plans a phase II ACACIA trial for HIV-1 infections (Combination therapy) (IV) (NCT06205602)